Youcare Pharmaceutical Group Co., Ltd. (688658.SH) Latest Company News

Oct 28, 2026, 09:26 UTC
Yuekang Pharmaceutical reported third-quarter 2026 revenue of 494 million yuan, down 16.47% year over year, and a net loss attributable to shareholders of 98.9133 million yuan; for the first nine months, revenue was 1.675 billion yuan, down 4.76%, and the attributable net loss was 204 million yuan.
Source:
- finance.sina.cn
Oct 15, 2026, 10:26 UTC
China's National Medical Products Administration approved Yuekang Pharmaceutical's Zihua Wenfei Zhike Granules for marketing as a Class 1.1 traditional Chinese medicine.
Source:
- finance.sina.cn
Oct 13, 2026, 10:50 UTC
The U.S. Food and Drug Administration approved a clinical trial application for YKYY036 injection developed by Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.
Source:
- finance.sina.cn
Oct 13, 2026, 10:50 UTC
China’s National Medical Products Administration approved clinical trials of YKYY036 injection, developed by Yuekang Pharmaceutical subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Yuekang Pharmaceutical Group Hangzhou Tianlong Pharmaceutical Co.
Source:
- finance.sina.cn
Oct 13, 2026, 10:48 UTC
Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Yuekang Pharmaceutical Group Hangzhou Tianlong Pharmaceutical Co., Ltd. received China clinical-trial approval for YKYY036 injection for obesity or overweight, and Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. also received U.S. clinical-trial approval.
Source:
- finance.sina.cn
Aug 20, 2026, 10:41 UTC
Yuekang Pharmaceutical announced it will invest 45 million yuan of excess raised funds into a small nucleic acid drug R&D project, covering three investigational drugs.
Source:
- finance.sina.cn
Aug 20, 2026, 10:41 UTC
Yuekang Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 105 million yuan, compared with a loss of 98.8291 million yuan in the same period last year.
Source:
- finance.sina.cn
Aug 5, 2026, 09:12 UTC
Yuekang Pharmaceutical received NMPA approval to conduct clinical trials for its YKYY017 nebulized inhalation agent with a new indication for treating and preventing respiratory infections related to human coronavirus OC43 (HCoV-OC43).
Source:
- finance.sina.cn
- finance.sina.cn
Aug 4, 2026, 09:18 UTC
Yuekang Pharmaceutical: Controlling shareholder's 1.8847 million shares unfrozen, all shares now unfrozen.

688658.SH

Yuekang Pharmaceutical reported third-quarter 2026 revenue of 494 million yuan, down 16.47% year over year, and a net loss attributable to shareholders of 98.9133 million yuan; for the first nine months, revenue was 1.675 billion yuan, down 4.76%, and the attributable net loss was 204 million yuan.

China's National Medical Products Administration approved Yuekang Pharmaceutical's Zihua Wenfei Zhike Granules for marketing as a Class 1.1 traditional Chinese medicine.

The U.S. Food and Drug Administration approved a clinical trial application for YKYY036 injection developed by Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

China’s National Medical Products Administration approved clinical trials of YKYY036 injection, developed by Yuekang Pharmaceutical subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Yuekang Pharmaceutical Group Hangzhou Tianlong Pharmaceutical Co.

Yuekang Pharmaceutical announced it will invest 45 million yuan of excess raised funds into a small nucleic acid drug R&D project, covering three investigational drugs.

Yuekang Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 105 million yuan, compared with a loss of 98.8291 million yuan in the same period last year.

Yuekang Pharmaceutical received NMPA approval to conduct clinical trials for its YKYY017 nebulized inhalation agent with a new indication for treating and preventing respiratory infections related to human coronavirus OC43 (HCoV-OC43).

Yuekang Pharmaceutical: Controlling shareholder's 1.8847 million shares unfrozen, all shares now unfrozen.